On this day in Santa Clarita history, MannKind Corporation announced the FDA approval of AFREZZA, a fast-acting diabetes medication that is taken through inhalation. The medicine was introduced as an alternative to injection; patients are given an inhaler to use before meals, with the levels peaking 12 to 15 minutes after administration and lasting up to 3 hours. “Approval of ...

A Valencia biomedical company announced the release of a first-of-its-kind insulin inhaler, Afrezza, in a statement. Don’t miss a thing. Get breaking Santa Clarita news alerts delivered right to your inbox. Sanofi and Valencia-based MannKind Corp. announced Afrezza (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription in U.S. retail pharmacies nationwide. Afrezza is approved by the U.S. ...

The MannKind Corp. announced that it has receive the FDA approval for its candidate diabetes treatment, Afrezza. The announcement came after the close of trading Friday.